Skip to main content
. 2019 Mar 13;155(5):625–627. doi: 10.1001/jamadermatol.2018.5595

Table 2. Odds Ratios of Poor Outcomes of IS Patients vs IC Controls Stratified by Number of Tumors and Adjusted for Brigham and Women's Hospital (BWH) and American Joint Committee on Cancer, 8th Edition (AJCC-8)a Staging Criteria.

SCCs, No. LR NM ITM Any PO
OR (95% CI) P Value OR (95% CI) P Value OR (95% CI) P Value OR (95% CI) P Value
Unadjusted
1 0.51 (0.11-2.35) .39 7.18 (0.64-81.06) .11 3.57 (0.49-26.06) .21 1.07 (0.33-3.45) .91
2-9 10.82 (2.31-50.71) .002 NA NA NA NA 11.95 (2.56-55.76) .002
Adjusted for BWH stage
1 0.53 (0.11-2.47) .05 10.00 (0.81-123.99) .07 4.88 (0.60-39.91) .14 1.15 (0.35-3.81) .82
2-9 11.62 (2.33-57.81) .003 NA NA NA NA 13.52 (2.69-67.97) .002
Adjusted for AJCC-8 stage
1 0.54 (0.12-2.52) .44 9.35 (0.78-112.41) .08 4.83 (0.61-38.26) .14 1.16 (0.35-3.80) .81
2-9 11.55 (2.40-55.58) .002 NA NA NA NA 13.29 (2.74-64.47) .001

Abbreviations: IC, immunocompetent patients; IS, immunosuppressed; ITM, in-transit metastases; LR, local recurrence; NA, not applicable; NM, nodal metastases; PO, poor outcomes; SCC, squamous cell carcinoma.

a

The AJCC-8 adjusted odds ratios were calculated for tumors limited to the head and neck region.